FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?

Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in...

Full description

Bibliographic Details
Main Authors: Csongor G. Lengyel, Sadaqat Hussain, Andreas Seeber, Sara Jamil Nidhamalddin, Dario Trapani, Baker S. Habeeb, Essam Elfaham, Syed Ayub Mazher, Fahmi Seid, Shah Z. Khan, Khalid El Bairi, Andrew Odhiambo, Sara C. Altuna, Angelica Petrillo
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Life
Subjects:
fibroblast growth factor receptors
FGFR fusions
next generation sequencing
first line
target therapy
FGFR inhibitors
Online Access:https://www.mdpi.com/2075-1729/12/1/81

Internet

https://www.mdpi.com/2075-1729/12/1/81

Similar Items